Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform 2025-07-14 15:38
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO 2025-07-14 08:00
Angel Yeast Unveils 2024 Sustainability Report, Showcasing Commitment to Green Practices and Innovation 2025-07-11 15:18
Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody 2025-07-10 19:00
GenScript Biotech Earns EcoVadis Silver Medal, Ranking in Top 15% Globally for Sustainability 2025-07-09 20:32
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial 2025-07-09 20:00
First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 2025-07-09 11:14
LakeShore Biopharma Announces US$15 Million Private Placement Financing 2025-07-08 19:25
WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities 2025-07-08 10:41
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo) 2025-07-08 10:08
WuXi AppTec Receives MSCI ESG AAA Leader Rating 2025-07-07 20:08
Nuevocor Strengthens Board with Appointment of Thierry Abribat 2025-07-07 13:00
ESG | HitGen Releases Its Inaugural Sustainability Report 2025-07-04 19:00
Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results 2025-07-03 20:30
MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform 2025-07-03 18:07
So-Young Regains Compliance with Nasdaq Minimum Bid Price Requirement 2025-07-03 17:00
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy 2025-07-03 14:46
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations 2025-07-03 08:08
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001 2025-07-03 07:09
SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response 2025-07-02 23:00